Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (2.999.689 €): Eine gemeinschaftsbasierte HPV-Screening-Implementierung in Ländern mit niedrigem Einkommen Hor 18.02.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Eine gemeinschaftsbasierte HPV-Screening-Implementierung in Ländern mit niedrigem Einkommen
Cervical cancer is the 4th most common cancer in women worldwide, with up to 85% of the burden in resource-restricted countries. Early detection of precancer has shown to be successful in reducing cancer incidence and mortality. However, a global implementation of this approach is hampered by culture and resource differences between countries. We propose to evaluate the acceptability, feasibility and cost-effectiveness of the ELEVATE cervical cancer screening tool in low-income countries (LIC). The tool is a portable, battery-powered device compatible with self-sampling and comprises an HPV DNA test as well as a proteomic biomarkers detection sensor and will be offered to women in Ethiopia, Cambodia, Mozambique and Uganda. This multidisciplinary consortium, led by Ghent University (Belgium), brings together social scientists, health economists and biosensor experts from Europe and the selected countries with industry partners. The approach is three-fold: social science investigations will be conducted to understand current screening practices and to define a tailored strategy, including the ELEVATE tool, embedded in the current health system. Secondly, engineers will validate the self-testing device and will adapt it to reduce the unit price and to enable large-scale manufacturing at an affordable cost. Finally, public health specialists and health economists will evaluate the implementation of the new screening tool to assess its appropriateness and cost-effectiveness. For the latter objective, an intervention will be implemented: in the first arm, the different steps of current cervical cancer screening practices will be optimized (awareness, pre-and post-counseling and referral). In the second arm, the same strategy will be applied in combination with the new point-of-care screening device. Integral part of CHILI is to maximize the use of the new screening tool in low-resource settings in collaboration with national stakeholders and health care providers.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. | 123.650 € |
| Fundico BVBA | 120.000 € |
| Jimma University | 249.673 € |
| Labman Automation Ltd. | 319.434 € |
| Microliquid SL | 302.839 € |
| National Institute FOR Public Health | 218.448 € |
| Universidade Eduardo Mondlane | 250.213 € |
| Universidade Nova de Lisboa | 54.138 € |
| Universitaet Greifswald | 199.813 € |
| Universitat Rovira i Virgili | 257.676 € |
| Universiteit Gent | 678.544 € |
| Uvri Clinical Research Program Initiative Ltd. | 225.264 € |
Quelle: https://cordis.europa.eu/project/id/964418
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
